Order results by:
| Issue | Title | |
| Vol 17, No 2 (2024) | Approaches to determining the cost of laboratory tests | Abstract similar documents |
| I. I. Khayrullin, V. V. Omelyanovskiy, R. V. Gostishchev, O. A. Sukhorukikh, S. A. Kovaleva, B. G. Gorodetsky | ||
| "... Background. Determining the cost of laboratory tests is a significant factor in the context ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... (medical, social etc.) throughout their life and the cost of the care has never been calculated in Russia ..." | ||
| Vol 17, No 4 (2024) | Development of a classification of anesthetic management methods and protocols for calculating financial costs | Abstract similar documents |
| D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov | ||
| "... Background. The costs of anesthetic support represent a significant and essential component ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| "... on the analysis of its cost and effectiveness in patients with chronic pain syndrome in pancreatic cancer ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... with an eosinophilic phenotype by means of a modeling method. Cost calculations were performed in a mathematical model ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents using cost-of-illness analysis | Abstract similar documents |
| O. S. Mikhaylova, A. V. Krikova | ||
| "... Background. The cost-of-illness (COI) analysis allows to estimate and plan costs for calculations ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... in terms of overall survival and progression-free survival. Therefore, a cost minimization analysis method ..." | ||
| Vol 14, No 3 (2021) | Health economic evaluation of risdiplam in patients with spinal muscular atrophy | Abstract similar documents |
| А. S. Kolbin, А. А. Kurylev, Yu. Е. Balykina, М. А. Proskurin, S. А. Mishinova | ||
| "... , because having equal effectiveness, it’s use is associated with lower direct medical costs. ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... using the cost of illness analysis in a model developed in Microsoft Excel 2016 (Microsoft, USA ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... for discussion. Despite the higher cost of lanreotide compared to octreotide, the former may have an advantage ..." | ||
| Vol 15, No 1 (2022) | The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, A. R. Kasimova, A. A. Kurylev, A. E. Bem | ||
| "... in the Federal Program of High-Cost Nosologies (HCN). Material and methods. In the CyberLeninka and eLibrary ..." | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... was used for the estimation of direct medical costs associated with different medications. Costminimization ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... Introduction. Presently, the willingness-to-pay threshold (cost-effectiveness threshold ..." | ||
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy | Abstract similar documents |
| I. N. Dyakov, S. R. Varfolomeеva | ||
| "... data. The methods of pharmacoeconomic analysis included a clinical-economic analysis (cost ..." | ||
| Vol 13, No 3 (2020) | The evaluation of the balance of standard rates within the program on state guarantees to deliver free medical care to the citizens of the Russian Federation | Abstract similar documents |
| D. V. Fedyaev, S. A. Kovaleva, K. V. Gerasimova | ||
| "... costs in the subjects of the RF was based on the Decrees of the Government for 2019 and 2020 ..." | ||
| Vol 14, No 3 (2021) | Review of methods for planning the scope of medical care and financing of the healthcare system by the subjects of the Russian Federation | Abstract similar documents |
| S. A. Kovaleva, D. V. Fedyaev, N. N. Sisigina | ||
| Vol 17, No 2 (2024) | Methodology of forming a model of diagnosis-related groups for cases of medical care using surgery performed by laparoscopic access | Abstract similar documents |
| I. A. Zheleznyakova, O. A. Volkova, E. I. Rumiantseva, I. A. Mikhailov, D. V. Fedyaev, A. V. Zuev, O. S. Plakhotnik, G. V. Trifonova, T. S. Vakhrusheva, E. S. Samsonova, V. V. Omelyanovskiy | ||
| "... of DRGs in the context of each profile, and calculation of cost-intensity coefficients. Results. Due ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... cancer (NSCLC). Materials and methods. The calculations included the direct costs of the healthcare ..." | ||
| Vol 17, No 4 (2024) | Standardized methodology for calculating the cost of medical care funded by government sources | Abstract similar documents |
| M. A. Sdvizhkova, S. A. Kovaleva, D. V. Fedyaev, V. V. Omelyanovskiy | ||
| "... . Efficient allocation of financial resources is becoming a priority. Calculating the cost of MC is considered ..." | ||
| Vol 14, No 2 (2021) | Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, V. S. Krysanova, T. N. Ermolaeva, K. I. Polyakova, K. A. Kokushkin | ||
| "... of the Moscow Region. Results. The analysis of cost of drug therapy and medical services per 1 case ..." | ||
| Vol 13, No 3 (2020) | Economic burden of systemic sclerosis: systematic review | Abstract similar documents |
| D. L. Klabukova, V. S. Krysanova, T. N. Ermolaeva, M. V. Davydovskaya, K. A. Kokushkin | ||
| "... of connective tissue. This disease has a significant negative impact on the patient’s quality of life and has ..." | ||
| Vol 13, No 3 (2020) | Regulatory framework of the oncological medical care provision | Abstract similar documents |
| S. N. Tishkina, V. E. Matskevich, Yu. A. Ledovskikh, E. V. Semakova, V. V. Omelyanovskiy | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... Objective: to evaluate cost-effectiveness and budget impact of using single and dual chamber ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... , including the dependency on the status of blood coagulation, as well as cost data. The analysis was carried ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... . The modeling was applied for cost minimization analyzis of using compared therapy regimens with comparable ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... . Objective: to evaluate the clinical and cost-effectiveness of using ATZ and Durv as first-line therapy ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... )), the cost-effectiveness analysis was used. The cost analysis included only direct medical costs: drugs ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... costeffectiveness analysis and pharmacoeconomic modeling were used. When assessing the economic costs of treatment ..." | ||
| Vol 16, No 4 (2023) | Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: modeling results | Abstract similar documents |
| V. I. Ignatyeva, D. Yu. Ovsyannikov, A. E. Tsygankov, E. E. Yagnenkova, V. R. Amirova, M. M. Maryanyan, A. S. Mokrova | ||
| "... months, 12 – <24 months, and 24 – 60 months. The costs of medical care were determined according ..." | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in children | Abstract similar documents |
| A. R. Kasimova, A. S. Kolbin | ||
| "... tonsillopharyngitis)", the direct medical costs of medical care were determined. The cost of basic therapy of 1 case ..." | ||
| Vol 17, No 4 (2024) | Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... Objective: to comparatively assess the weighted average costs associated with the use ..." | ||
| Vol 16, No 1 (2023) | Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 | Abstract similar documents |
| D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin | ||
| "... system of the Russian Federation considering cost data for 2022 in the population of women ..." | ||
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... pharmacoeconomic study was updated considering a decrease in the cost of pembrolizumab after the generic form ..." | ||
| 1 - 34 of 34 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
